NASDAQ:PGNXProgenics Pharmaceuticals Stock Price, Forecast & News

Progenics Pharmaceuticals' stock was trading at $3.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PGNX stock has increased by 11.4% and is now trading at $4.2450. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Progenics Pharmaceuticals.

Progenics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Progenics Pharmaceuticals.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) issued its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.03. The biotechnology company earned $6.25 million during the quarter. Progenics Pharmaceuticals had a negative return on equity of 129.46% and a negative net margin of 180.28%. View Progenics Pharmaceuticals' earnings history.

3 analysts have issued 12-month price targets for Progenics Pharmaceuticals' shares. Their forecasts range from $10.00 to $14.00. On average, they expect Progenics Pharmaceuticals' share price to reach $12.00 in the next year. This suggests a possible upside of 182.7% from the stock's current price. View analysts' price targets for Progenics Pharmaceuticals.

Media coverage about PGNX stock has been trending somewhat negative on Saturday, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Progenics Pharmaceuticals earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the next several days. View the latest news aboutProgenics Pharmaceuticals.

Progenics Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 5,530,000 shares, a decline of 5.6% from the April 30th total of 5,860,000 shares. Based on an average daily volume of 965,800 shares, the short-interest ratio is currently 5.7 days. Approximately 7.1% of the shares of the stock are sold short. View Progenics Pharmaceuticals' Current Options Chain.

Some companies that are related to Progenics Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Vonage (VG), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Caterpillar (CAT), Imax (IMAX), Novavax (NVAX), Cara Therapeutics (CARA), Opko Health (OPK), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX).

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

Progenics Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.99%), State Street Corp (5.35%), Geode Capital Management LLC (1.44%), Alliancebernstein L.P. (1.44%), Bank of New York Mellon Corp (1.07%) and Nuveen Asset Management LLC (1.06%). Company insiders that own Progenics Pharmaceuticals stock include Lte Partners, Llc and Velan Capital, LP. View institutional ownership trends for Progenics Pharmaceuticals.

PGNX stock was sold by a variety of institutional investors in the last quarter, including CNH Partners LLC, BlackRock Inc., Wells Fargo & Company MN, Rafferty Asset Management LLC, Two Sigma Investments LP, Bank of New York Mellon Corp, UBS Group AG, and Arizona State Retirement System. View insider buying and selling activity for Progenics Pharmaceuticals.

PGNX stock was acquired by a variety of institutional investors in the last quarter, including Yakira Capital Management Inc., Wolverine Asset Management LLC, Beryl Capital Management LLC, Alliancebernstein L.P., IndexIQ Advisors LLC, CSS LLC IL, Nuveen Asset Management LLC, and State Street Corp. Company insiders that have bought Progenics Pharmaceuticals stock in the last two years include Lte Partners, Llc, and Velan Capital, LP. View insider buying and selling activity for Progenics Pharmaceuticals.

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PGNX stock can currently be purchased for approximately $4.25.

Progenics Pharmaceuticals has a market capitalization of $367.62 million and generates $34.99 million in revenue each year. The biotechnology company earns $-68,550,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe.

The official website for Progenics Pharmaceuticals is www.progenics.com.

Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]